300204.SZ深圳证券交易所 · 创业板 ChiNext
Staidson Biopharmaceuticals 舒泰神
Chemical Pharmaceuticals 化学制药
¥20.02−¥0.86 · −4.12%
Open 开盘
¥20.65
High 最高
¥21.18
Low 最低
¥20.01
Prev Close 昨收
¥20.88
Volume 成交量
1,442.7万股
Turnover 成交额
¥2.95亿
Mkt Cap 总市值
¥108亿
P/E 市盈率
−120.6×
Recent Activity 近期动态All Filings 全部公告 →
14 significant filings since 30 May 2026: 8 on share issue, 2 on guarantee or financial assistance and 2 on new listing, and 2 other kinds. The latest, on 21 Sep 2026: 关于公司向银行申请贷款并提供抵押反担保的进展公告（七）. 1 unverified report logged, the latest on 24 Aug 2026.
自 30 May 2026 起有 14 份重大公告：share issue 8 份、guarantee or financial assistance 2 份、new listing 2 份，另有 2 类。最新一份（21 Sep 2026）：关于公司向银行申请贷款并提供抵押反担保的进展公告（七）。记录了 1 条未经核实的报道，最新一条见于 24 Aug 2026。
10.0020.0030.0040.0050.00
Volume 成交量
9,083.8万
20112015201820222026
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Relative Value 同业比较
Chemical Pharmaceuticals 化学制药 · 158 listed peers
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥108亿 | ¥63亿 | 44th highest of 158 · 158 家中第 44 高 | |
| Trailing P/E 市盈率 | — | 38.6x | No value 无数据 | |
| P/B 市净率 | 11.8x | 2.5x | 13th highest of 157 · 157 家中第 13 高 | |
| Revenue Growth 营收增速 | -26.0% | 1.6% | 9th lowest of 156 · 156 家中第 9 低 | |
| Profit Growth 净利增速 | -49.2% | 1.9% | 23rd lowest of 158 · 158 家中第 23 低 | |
| Gross Margin 毛利率 | 74.1% | 50.2% | 32nd highest of 155 · 155 家中第 32 高 | |
| Net Margin 净利率 | -41.8% | 9.8% | 12th lowest of 157 · 157 家中第 12 低 | |
| Return on Equity 净资产收益率 | -4.5% | 3.1% | 17th lowest of 157 · 157 家中第 17 低 | |
| Debt to Assets 资产负债率 | 39.3% | 28.0% | 53rd highest of 158 · 158 家中第 53 高 | |
| Grade Score 评级得分 | 24 | 51 | 12th lowest of 157 · 157 家中第 12 低 |
Statement figures are for the period to 30 Jun 2026, filed by 158 of 158 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，158 家同业中 158 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
Largest Peers 主要同业
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Beone Medicines 百济神州 | ¥3,979亿 | 92.9x | 11.2x | 26.8% | 14.7% | 9.9% | B |
| Hengrui Pharma 恒瑞医药 | ¥2,977亿 | 38.5x | 4.6x | -1.9% | 28.9% | 8.0% | C |
| Haisco Pharmaceutical Group 海思科 | ¥699亿 | 73.7x | 14.3x | 54.7% | 27.5% | 18.3% | B |
| CSPC Innovation Pharmaceutical 石药创新 | ¥620亿 | 60.6x | 15.8x | 208.7% | 47.9% | 38.2% | B |
| Sichuan Kelun Pharmaceutical 科伦药业 | ¥618亿 | 33.8x | 2.5x | -2.7% | 16.1% | 4.6% | C |
| Fosun Pharma 复星医药 | ¥610亿 | 18.0x | 1.3x | 4.8% | 10.5% | 3.5% | D |
| Innocare 诺诚健华 | ¥528亿 | 57.5x | 6.9x | 55.5% | 21.1% | 3.2% | C |
| Allist 艾力斯 | ¥469亿 | 17.5x | 5.5x | 39.9% | 46.4% | 19.7% | B |
| Huadong Medicine 华东医药 | ¥457亿 | 13.2x | 1.8x | 1.8% | 8.3% | 7.3% | C |
| Shenzhen Salubris Pharmaceuticals 信立泰 | ¥337亿 | 50.0x | 3.9x | 16.3% | 15.8% | 4.3% | C |
| Humanwell Healthcare ST人福 | ¥307亿 | 15.1x | 1.6x | -0.0% | 14.0% | 6.8% | C |
| Apeloa Pharmaceutical 普洛药业 | ¥293亿 | 34.5x | 4.5x | -11.4% | 10.8% | 8.1% | D |
| Zelgen 泽璟制药 | ¥288亿 | 52.5x | 16.8x | 220.9% | 53.1% | 45.7% | B |
| Dizal Pharmaceutical 迪哲医药 | ¥263亿 | — | 23.2x | 47.2% | -40.8% | -17.2% | D |
| Staidson Biopharmaceuticals 舒泰神 | ¥108亿 | — | 11.8x | -26.0% | -41.8% | -4.5% | E |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。